PMID- 15117989
OWN - NLM
STAT- MEDLINE
DCOM- 20040527
LR  - 20151119
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 22
IP  - 9
DP  - 2004 May 1
TI  - Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by 
      the Spanish Hodgkin's Lymphoma Study Group.
PG  - 1664-73
AB  - PURPOSE: Current therapies fail to cure a significant proportion of patients with 
      Hodgkin's lymphoma (HL). Predictive systems for stratification of the disease and 
      selection of treatment based on sets of clinical variables, such as the 
      international prognostic score (IPS), are of relatively small practical value. 
      The predictive use of biologic parameters has so far provided limited and 
      inconsistent results. Here we explore the influence of a set of molecular markers 
      on the outcome of HL. PATIENTS AND METHODS: Forty molecular markers involved in 
      B-cell differentiation and activation, signal transduction, cell cycle, and 
      apoptosis control were analyzed in 259 classic HL patient cases by using tissue 
      microarrays. Univariate analysis was performed to evaluate the influence of 
      markers on favorable outcome (complete remission of > 12 months). Significant 
      variables were included in a multivariate logistic regression analysis, and the 
      probability of favorable outcome was estimated. RESULTS: Univariate analysis 
      revealed four molecular markers that predicted outcome, and the multivariate 
      analysis showed p53, Bcl-X(L), and terminal deoxynucleotidyl transferase-mediated 
      deoxyuridine triphosphate-biotin nick-end labeling (TUNEL) to have independent 
      significance. The combination of these factors determined two groups of patients 
      (group I, zero to one factor; group II, two to three factors) with a probability 
      of a favorable outcome of.948 and.687, respectively. A multivariate Cox's model 
      shows that these biologic risk groups have special predictive power in low-IPS 
      patients. CONCLUSION: The data from this exploratory study suggest that the 
      accumulation of molecular events seems to influence the outcome of HL, 
      particularly in the low-IPS group.
FAU - Montalban, Carlos
AU  - Montalban C
AD  - Medicina Interna, Hematologia and Unidad de Bioestradistica Clinica, Hospital 
      Ramon y Cajal, Madrid, Spain.
FAU - Garcia, Juan F
AU  - Garcia JF
FAU - Abraira, Victor
AU  - Abraira V
FAU - Gonzalez-Camacho, Leocricia
AU  - Gonzalez-Camacho L
FAU - Morente, Manuel M
AU  - Morente MM
FAU - Bello, Jose L
AU  - Bello JL
FAU - Conde, Eulogio
AU  - Conde E
FAU - Cruz, Miguel A
AU  - Cruz MA
FAU - Garcia-Sanz, Ramon
AU  - Garcia-Sanz R
FAU - Garcia-Larana, Jose
AU  - Garcia-Larana J
FAU - Grande, Carlos
AU  - Grande C
FAU - Llanos, Marta
AU  - Llanos M
FAU - Martinez, Rafael
AU  - Martinez R
FAU - Flores, Eduardo
AU  - Flores E
FAU - Mendez, Miguel
AU  - Mendez M
FAU - Ponderos, Concepcion
AU  - Ponderos C
FAU - Rayon, Concepcion
AU  - Rayon C
FAU - Sanchez-Godoy, Pedro
AU  - Sanchez-Godoy P
FAU - Zamora, Javier
AU  - Zamora J
FAU - Piris, Miguel A
AU  - Piris MA
CN  - Spanish Hodgkin's Lymphoma Study Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Biomarkers, Tumor)
SB  - IM
CIN - J Clin Oncol. 2005 May 1;23(13):3158-9; author reply 3159-60. PMID: 15860883
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Apoptosis
MH  - Biomarkers, Tumor/*analysis
MH  - Cell Cycle
MH  - Cell Differentiation
MH  - Child
MH  - Female
MH  - Hodgkin Disease/*pathology
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Nick-End Labeling
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging/*methods
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Survival Analysis
EDAT- 2004/05/01 05:00
MHDA- 2004/05/28 05:00
CRDT- 2004/05/01 05:00
PHST- 2004/05/01 05:00 [pubmed]
PHST- 2004/05/28 05:00 [medline]
PHST- 2004/05/01 05:00 [entrez]
AID - JCO.2004.06.105 [pii]
AID - 10.1200/JCO.2004.06.105 [doi]
PST - ppublish
SO  - J Clin Oncol. 2004 May 1;22(9):1664-73. doi: 10.1200/JCO.2004.06.105.